Day: July 9, 2024

Highlights Company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently commenced clinical study, broader pipeline opportunities, and overall mission and vision NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) — Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company advancing a novel cannabinoid-based research platform, today issued the following letter to shareholders from its Chief Executive Officer and Chairman, Shlomo Pilo. Dear Fellow Shareholders, As we enter the second half of 2024, Raphael Pharmaceutical has reached an exciting and pivotal moment in its journey to create new, improved, cost-effective treatment options for a variety of...

DALLAS, July 09, 2024 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that its affiliated manager, Hark Capital (“Hark”), a provider of flexible Net Asset Value (“NAV”) credit solutions to lower middle market sponsors, announced the final closing of Hark Capital IV (“Fund IV” or the “Fund”). With $645 million in capital commitments, inclusive of LP and GP commitments, the Fund meaningfully exceeded its $500 million cover. The Fund received strong reups from its existing limited partners as well as significant commitments from new investors. Hark’s limited partners include prominent U.S. insurance companies, public pension plans, and family offices. The total capital commitments for Fund IV represent more than a 60% increase compared to its Fund III, and an increase of approximately...

EMERYVILLE, Calif., July 09, 2024 (GLOBE NEWSWIRE) — NMI Holdings, Inc., (NASDAQ: NMIH), the parent company of National Mortgage Insurance Corporation (National MI), today announced that it will report results for its second quarter ended June 30, 2024 after the market close on Tuesday, July 30, 2024. The company will hold a conference call and live webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The webcast will be available on the company’s website at https://ir.nationalmi.com/events-and-presentations. The call can be accessed by dialing (844) 481-2708 in the U.S. or (412) 317-0664 internationally by referencing NMI Holdings, Inc. A replay of the webcast as well as the earnings press release and any supplemental information will be available on the company’s website. About NMI Holdings NMI Holdings, Inc....

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES MONTRÉAL, July 09, 2024 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (CSE: CDPR) (OTCPK: GPPRF) (FRA: N8HP) (“CDPR” or the “Corporation”) is pleased to announce the closing of its previously announced non-brokered private placement, for total aggregate gross proceeds of $3,298,000 (the “Offering”). CDPR issued 32,980,000 units of the Corporation (“Units”) at a price of $0.10 per Unit, each consisting of one common share (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles its holder to purchase one Common Share at an exercise price of $0.15 per Common Share for a period of 24 months, subject to acceleration in certain circumstances (see news release...

Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has settled its lawsuit against Amarex Clinical Research LLC (“Amarex”), the Company’s former Contract Research Organization (“CRO”). The material terms of the settlement are as follows: (i) Amarex will pay $12,000,000 to CytoDyn, $10,000,000 was paid upon execution of the agreement and the remainder to be paid within the next 12 months; (ii) the surety bond, valued at $6,500,000, will be released...

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System. BRAINTREE, Mass., July 09, 2024 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute, has completed its first clinical procedure in a patient utilizing the LIBERTY® Endovascular Robotic Surgical System. The clinical case was performed shortly after last week’s announcement regarding the participation of Baptist Hospital of Miami as a clinical trial site. Baptist Hospital is the second clinical site to perform a clinical...

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. Eastern Time, on July 11, 2024. Beginning with the opening of trading on July 11, 2024, Clene’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the Company’s existing trading symbol “CLNN.” The CUSIP number for the Company’s publicly traded warrants will not change. The reverse stock split...